Phase 2 N=50 Psychopharmacology for Cocaine Dependence - Buspirone
Cocaine Dependence
Primary: Attentional Bias as Assessed by Score on the Stroop Task — -13.90333; 27.118; -9.361269; 15.35407 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=1,379 GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Sepsis
Primary: Percentage of Participants With 28-Day All Cause Mortality — 26.9; 25.8; 31.3 Percentage of participants — p=0.329
Phase 2 N=36 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia
Primary: Percentage Patients With an Increase of at Least 10 Percentage Points in Donor T-cell Chimerism — 60; 30; 33.3 percentage of participants
N/A N=63 Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
Graft Versus Host Disease
Primary: CXCL10 in Skin — 273; 41; 7.5 Skin CXCL10 femtograms/micrograms — p=<0.01
Phase 3 N=551 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control
Asthma
Primary: Mean Change From Baseline (BL) in St. George's Respiratory Questionnaire (SGRQ) Score at Week 24 — -7.9; -15.6 Scores on a scale — p=<0.001
N/A N=18 PEMF: an Adjunct Therapy for Anterior Uveitis
Anterior Uveitis · Iritis
Primary: Inflammation Grade at Day 7 — 0.625; 1.444 units on a scale
N/A N=89 Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%
Post Surgical Pain
Primary: Primary Outcome Variable is Post Operative Sensory Block Duration — 12.1; 22.3; 23.3; 21.2 hours
N/A N=15 Evaluation of Antimicrobial Soft Silicone, Silver Containing, Foam Dressing, Mepilex Border Ag, in Second Degree Burns
Burns
Primary: Evaluate the Experience of Using Mepilex Border Ag ( a Silver Dressing) in Normal Clinical Practice — 9 burns healed
Phase 3 N=27 Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)
Insomnia · Obstructive Sleep Apnea
Primary: Sleep Onset Latency — 9.7; 34.4 minutes
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
Phase 3 N=1,205 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL — 0.73; 0.65; 1.33 events/year — p=<0.001
N/A N=152 Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation
Atrial Fibrillation
Primary: Percentage of Patient With Atrial Fibrillation Termination at the End of the Procedure — 95; 60 Percentage of participants
Phase 2 N=48 Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin
Primary: Number of Donors Requiring a Second Collection to Obtain a Minimum CD34/Kg (2 x 10^6) Necessary for Allogeneic Stem Cell Transplantation — 4 Participants
Phase 2 N=54 Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Multiple Sclerosis · Cognition
Primary: Paced Auditory Serial Addition Task (PASAT) — 2.24; 3.38 correct responses — p=0.05
N/A N=92 Past Pain Experience and Perception of Experimental Pain
Schizophrenia · Major Depression
Primary: Visual Analog Scale Evaluation for the Pre-fixed Pressure Test — 2.8; 2.1; 1.2 units on a scale — p=0.121